Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus IMRT in Recurrent Nasopharyngeal Carcinoma
NCT03666221Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Nov 2014
- Primary completion
- Apr 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in nasopharyngeal carcinoma (NPC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Tumor response rate at 3 months and Toxicity of combined treatment at 3 months. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03666221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03666221.